FDA approves Voraxaze from BTG for ultra-rare indication

The US FDA has granted approval for BTG's biologics license application for Voraxaze (glucarpidase) to treat high dose methotrexate toxicity, an ultra-rare indication with only 300 sufferers in the US per year.